Scott Runyon

Director, Organic and Medicinal Chemistry

Education

  • PhD, Medicinal Chemistry, Medical College of Virginia
  • BS, Chemistry, Muhlenberg College

Press Inquiries

To request an interview, contact our Media Relations team.
+1 919 541 7340 news@rti.org

Scott Runyon, Ph.D., is RTI’s principal investigator conducting synthetic medicinal chemistry research. Currently, his lab is developing small-molecule agonists for neuropeptide S and the APJ GPCR’s.

Since joining RTI in 2001, Dr. Runyon has focused on developing novel therapeutics, including:

  • Small-molecule kappa opioid antagonists
  • Dopamine transporter inhibitors
  • GABA allosteric modulators (neuroactive steroid scaffold)
  • Non-hormonal male contraceptives (indenopyridine scaffold)
  • Haptens and protein conjugates for nicotine and opiate vaccines
  • Orexin antagonists
  • Neurotensin modulators
  • Apelin and neuropeptide S peptide structure activity relationships
  • Small-molecule neuropeptide S agonists and antagonists
  • Small-molecule APJ/apelin agonists.

Dr. Runyon has extensive medicinal chemistry and drug development experience and has worked on teams, including, JDTic, a compound used to map the kappa opioid receptor. This project has progressed compounds to IND-ready and phase 1 clinical trials.